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ABSTRACT - This thesis investigates why some patients with duodenal
ulcer do not respond to blockade and how these patients should be
treated.
Part 1 examines the effect of cimetidi.'ne lg/day, cimetidine 2g/day
and vagotomy on nocturnal gastric secretion in nonresponders. Cimetidine
in either dose had no significant effect on volume of gastric secretion
but nocturnal intragastric acidity did show a significant decrease.
Vagotomy significantly decreased both volume and acidity of secretion.
These findings suggest that nonresponse to cimetidine may be due to
increased vagal drive.
Part 2 investigates vagal function further by measuring nocturnal
pepsin secretion in patients receiving cimetidine and ranitidine. Both
H2~receptor antagonists increased nocturnal pepsin secretion despite
reducing acid. Previous reports suggest cimetidine inhibits pepsin out¬
put. However, patients whose acidity is controlled well with cimetidine
have a rise in pH which, as pepsin is unstable at high pH values may
result in pepsin deactivation . Patients whose acidity is only poorly
controlled with cimetidine, therefore, do not denature pepsin, and as
blockade increases vagal drive, intragastric pepsin rises. Duodenal
ulcer activity correlates well with pepsin output. Thus, combination of
poor acidity control with rise in intragastric pepsin results in non-
response.
Studies were also performed to investigate the mechanism of incre¬
ased pepsin secretion. These suggested that histamine may inhibit vagal
drive and, therefore, blockade may increase vagal release. Cimetidine
in combination with atropine 4.8mg/day resulted in a significant re¬
duction of volume, acid and pepsin secretion. This latter result suggests
that cimetidine should be combined with an anticholinergic agent to
inhibit vagal drive and improve control of gastric secretion which




It has long been recognized that histamine is a potent stimulant of
gastric secretion, yet conventional antihistamines are of no benefit in
controlling gastric secretion. A leading article in the British Medical
Journal in 19A8 stated that "it is strange that on gastric secretion
alone, there has till now been no suggestion of antagonism between sub¬
stances (histamines and antihistamines) which are antagonists everywhere
else. It is likely that there is one simple explanation of this anomaly
which should well repay exploration". It was not until 1972 that Black
and colleagues finally provided this explanation by defining the H^
receptor (Black, Duncan, Durant, Ganellin and Parsons, 1972). Since
their report, numerous t^-receptor antagonists have been developed.
Clinical trials have shown these drugs to be efficacious in treat¬
ing peptic ulceration without side effects. Few drugs have such wide¬
spread use. Indications for treatment have included: oesophagitis
(Bennet, McCormick, Oliver, Celestin, 1978; Heading, Blackwell, Cameron,
1981), gastric erosions (Speranza, Basso, Bagorcine, Bianchi, Materia,
Firoani 1979(, emergency anaesthesia (Moore, Howe, Dundee, Johnston,
McCaughey, 1981), renal transplantation (Vanrenterghem, Roels, Michielsen,
1980), pancreatic insufficiency, and ileal resection (_Northf iel d,
Zentl er-Munro, Fitzpatirck, Fine, 19.8l)_, as well as gastric and duo¬
denal ulceration with their associated complications.
Despite enormous success, cimetidi.ne does not heal all duodenal
ulcers. After a six week course of therapy, healing rates are reported
around 75% with some 25% remaining unhealed (Burland, Hunt, Mills, and
Milton-Thompson, 1979). It is, at present, not known how these
cimetidine resistant ulcers should be treated and why they do not
respond to H^ blockade. This thesis attempts to answer these two
quest ions.
1.1 The problem of peptic ulceration. It has been estimated that in
the Western World, 10-15% of men and *4-15% of women are afflicted with
at least one attack of peptic ulcer during their lifetime (Venables 1979).
Studies from the United States, the Netherlands, Italy, and Sweden have
estimated that the total cost of peptic ulcer disease is ]% of the cost
of all diseases (Bodemar, Gottherd, Strom, Walen, Jonsson, Bjurulf 1979).
Approximately 1.5% of all days off work in the U.S.A. in 1975 were due
to peptic ulcer, costing an estimated 1330 million dollars which was
equivalent to 18.6 million working days (Bodemar, Gottherd, Strom,
Walen, Jonsson, Bjurulf 1979). In England and Wales, approximately
20 million working days are lost each year because of upper gastro¬
intestinal symptoms (Langman 1978).
Although the introduction of cimetidine brought a decrease in the
number of working days lost from duodenal ulcer disease (Bardhan 1981a;
Bodemar and Walen 1978), this decrease was only about 10% between 197*4-
75 and 1978-79 (Bardhan 1981a).
The cost of surgery for duodenal ulcer is difficult to estimate.
Inpatient stay after vagotomy is estimated at 15.1 days (Pounder 1981)
and inpatient treatment in the National Health Service in March 1981
was^75.00 per day. On these figures, the cost per operation is
1133 which does not include loss of earnings or the costs of recui
rent ulcer after surgery.
Culyer and Maynard (I98O) put the loss of earnings after vagotomy
at jE.1660 and suggested that the cost of surgery to the community was
in the region of £ 16000 per patient.
Although cimetidine has reduced the number of elective operations
for duodenal ulcer (Coggan, Lambert, Langman 1981; Venables 1981;
Hunt 1981a; Fineberg and Pearlman 1981), there were still some 660
operations per year performed for duodenal ulcer in the Northern
Region of the United Kingdom between 1977 and 1979.
1.2 The aetiology of duodenal ulcer. Present thoughts on the aetiology
of peptic ulceration suggest an imbalance between mucosal barrier versus
acid and pepsin secretion. The logical approach to treatment has,
therefore, been chanelled in one of these directions.
1.3 The mucosal barrier. Claude Bernard (1856) likened the stomach to
a perocelain pot, so introducing the concept of a mucosal barrier. This
concept is thought to be a dynamic equilibrium depending on gastric
mucosal blood flow (Moody, McGreevy, Zalewsky, Cheug, Simmons 1978;
Guth, Bauman, Grossman, Aures, Elashoff 1978), cellular regeneration,
secretion of mucus, epidermal growth factor, prostaglandins (Grossman
1980), bicarbonate (Garner and Flemstrom 1978) and hydrogen ions
together with a dynamic gradient of acid concentration across the
mucous lining of the stomach (Rees and Turnberg 1981; Bahari, Rees,
and Turnberg 1981).
Caved S (deg1ycyrrhizinated liquorice) (Morgan, McAdam, Pacsoo,
Darnborough 1982; Tewari, and Trembalowics 1968), Denol (tripotassiurn
dicitrato bismuthate) (Martin, Hollander, May, Ravenscroft, Tweedle,
Miller 1981), carbenoxolone (Morgan, McAdam, Pacsoo, Walker, Simmons
1978) and sucralfate (Marks, Wright, Denyer, Garish, Luck 1980;
Martin, Farley, Gangon, Bensemana 1982) are all thought to act on the
mucosal barrier and have been shown to be of benefit in healing gastric
ulcer. Some reports also suggest these compounds are useful in
duodenal ulcer (Morgan, McAdam, Pacsoo, Darnborough 1982; Martin,
Hollander, May, Ravenscroft, Tweedle, Miller 1981; Reed and Davles
1978; Hollander 1981) .
l.A Peps i n. In 1752, Reaumir showed that meat was digested without
putrefaction by the regurgitated contents of his pet buzzard. His
findings were confirmed by Spallanzani (1783) using human gastric juice.
The proteolytic action of gastric juice was named "pepsin" by Schwann
in 1836.
The amount of pepsin in gastric juice may be measured using its
proteolytic activity to digest a known amount of haemoglobin substrate,
measuring the colour change spectrophotometrica11y, and comparing the
results with a known amount of crystalline hog pepsin treated in the
same way (Anson and Mirsky 1932). This technique may be improved by
using modified haemoglobin substrate (Berstad 1970) or radioactive
iodinated albumin (Klotz and Duval 1 1957) but the basic method remains
the same. Unfortunately, these analyses are time consuming because
they require incubation of gastric juice with substrate followed by
separation of substrate and products. They also suffer from not being
reproducible between centres because of the variable purity of
commercially available hog pepsin.
It is generally thought that in the basal state, pepsin output
parallels acid output (Janowitz and Hollander 1952; Hirschowitz and
London 1955; Woodward, Schapiro, Armstorng 1956; VanGoidsenhoven,
Wilkoff, Kirsner 1958). However, pepsin becomes denatured at high
pH values (Goulding, Borsook and Wasteneys 1927; Piper and Fenton
196A; Berstad 1982) and, therefore, low acid outputs with associated
high pH values will result in an apparently low pepsin output.
Vagal stimulation results in greater increase in pepsin secretion
than acid secretion and although pentagastrin fs a potent stimulant
of acid, it is not as potent at stimulating pepsin release (Venables,
Wheldon, Johnston 1975; Venables and Johnston 1969; Wilson, Dymock,
Cowley 197^; Berstad, Peterson, Roland, Liavig 1973). Thus different
mechanisms exist for controlling acid and pepsin secretion.
The greater secretion of pepsin after vagal stimulation has been
used clinically by Venables, Wheldon and Johnson (1975) and Gulvag and
Berstad (1982) who found that output of pepsin after a vagal stimulus
was a better prediction of the completeness of vagotomy than was acid
output.
According to Pollard and Augur 0968), Quincke first used the term
"peptic" in 1882 to describe a gastric ulcer, yet in the present day,
this term is used for any mucosal defect in the upper gastrointestinal
tract brought about by the action of acid and pepsin. The term obviously
implies that pepsin has a major role i"n the aetiology of this- disease.
During perfusion experiments on cat stomach, duodenum and jejunum,
Schiffrin and Warren (19^2) demonstrated that acid alone did not produce
ulceration unless combined with pepsin. They suggested that acid ulcer
was a misnomer and that more attention should be directed to the inac-
ti.vation of pepsin in the treatment of duodenal ulcer.
Although Hunt (1950a; 1950T>.) found no relative hypersecretion of
pepsin in patients with duodenal ulcer, most other workers have noted
increased intragastric pepsin secretion when compared with normal
individuals (.Venables 1969; Taylor 1970) and pepsin output has been
related to disease activity (Vanzant, Osterberg, Alvarez, Rivers 1933;
Taylor 1970; Venables 1969; Venables 1971; Elder 1975; Achord 1978).
Bonfils, Lewin, Vatier, Dubrasquet and Bader 0968] found a small
number of patients with excess pepsin secretion whom they classified
as having increased vagal drive; Pelican, Horcicka and Komenda (J969)
also found a group of patients with low basal acid and high basal pep¬
sin output who they suggested had a high vagal tone.
Despite these reports, compounds which neutralize pepsin have
not received as much attention as those which neutralize acid. In the
lay literature, novelist P.G. Wcdehouse (1921) had one of his character
asking for "pepsin" to cure his indigestion. Even in the medical liter¬
ature, pepsin inactivation does not receive much attention. In a
recently published 552 page book entitled "Advances in Ulcer Disease.
Proceedings of a symposium on the pathogenesis and therapy of ulcer
disease" (Hoitermul1er and Malagdelada 1980) pepsin received only one
paragraph which described how it may be inactivated by antacids.
Babkin and Komorov (1932) were the first to search for an antipeps
agent. Others have tried using:pepstatin (Umezawa, Aoyagi, Morishima,
Matsuzaki, Hamada, Takeuchi 1970; Christiansen, Svendsen, Guldager,
Christensen 1975), amylopectin (Sun and Ryan 1970; Cayer and Ruff in
1967), carrageenin (Anderson and Watt 1959), aluminium sucrose sulphate
(Yagamato, Ishimori, Sato et al, 1973), chondroitin sulphate (Cook and
Drill 1967) and hydrotalcite (Playle, Gunning, Llewellyn 197^0- Amylo¬
pectin has been shown to improve healing of gastric ulcer but all the
other agents are of no proven benefit - even when combined with an
anticholinergic agent to delay gastric emptying (Cocking 1972). One
possible explanation for this lack of effect of antipeptic agents is
that duodenal ulcer patients have high basal pepsin outputs and,
therefore, large quantities of inactivator should be necessary to
promote healing.
Anticholinergic agents inhibit secretion of both acid and pepsin
but if they are to be of clinical benefit, they need to be given tn
large doses which cause distressing side effects (ivey 1975).
1.5 Acid. In 1823, William Prout reported to the Royal Society that
the vomitus of three patients with dyspepsia contained free muriatic
(hydroch 1 or i c) ac i d "in great abundance". Prout's observations were
confirmed by William Beaumont (1833) during studies on his famous
patient, Alexis St. Martin, but it was not until 1910 that Schwartz
introduced the dictum "no acid - no ulcer". Since that time, decreased
acid secretion has formed the mainstay of treatment for duodenal ulcer
for the following reasons:
1}_ Despite a few reports (Janowi.tz and Hollander 1951;
Greenspan, Levy and Nechels 1951; Watkinson and James
1951; Schiff, Pugh and Watkins 1952; Isenberg, Spector,
Hootkin and Pitcher 1971; Korn and Faroozan 197^; Wald
and Burbige 1975) which have been challenged (Baron
1963; Baron 1975), it is generally belfeved that duo¬
denal ulceration in the presence of anacidity is
extremely rare.
2) A duodenal ulcer is highly likely in the presence of
a peak acid output of greater than 50 mmol/hr
(Baron 1973).
3) Duodenal ulcer is rare in patients with peak acid
outputs of less than 15 mmol/hr (Baron 1973).
4) A duodenal ulcer is usually present in the Zollinger-
Ellison syndrome (Zollinger and Ellison 1955) with its
associated hypersecretion of acid.
5) Measures which decrease acid output by medical or
surgical means usually result in ulcer healing.
Prior to the introduction of the histamine H^-receptor antagonists,
no really effective medical therapy was known for the treatment of
duodenal ulcer. Antacids decrease intragastric acidity over a twenty-
four hour period (Keenan, Hunt, Vincent, Wright and Milton-Thompson
1978) and have been shown to heal duodenal ulcers when g i'ven in large
doses (Peterson, Sturdevant, Franki et al 1977; Ippoliti, Sturdevant,
Isenberg et al 1978). However, high doses of antacids are associated
with significant side effects (Spencer and Lender 1979).
Several workers have tried to identify gastrin inhibitors
Gregory and Ivy 19^1; Uvnas 19^2) and others have tried dietary
manipulation (Lennard-Jones 19&5) in an attempt to decrease intragastric
acidity. None of these has any effect on the healing of duodenal ulcer.
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1.6 The importance of histamine. Histamine was first synthetised in
1907 (Windus and Vogt), but it was not until 1920 (Popiel ski) that it was
shown by work in dogs to be a potent stimulant of gastric secretion.
Carnot, Korskowski and Libert (1922) demonstrated a similar effect in
man.
Barger and Dale (1911) had identified histamine in extracts of
intestinal mucosa but it was left to Best, Dale, Dudley and Thorpe (1927)
to establish beyond doubt that histamine occurred naturally in the body
and was not a contaminant of tissue extracts.
Vagal stimulation was shown to result in histamine release in the
gastric lumen suggesting that histamine may have been a final common
pathway (Babkin, 1938). Emmelin and Kahlson (19^*0 concluded that
"during the cephalic and gastric phases, parietal secretion is excited
by a two state humoral mechanism, the first stage involving the liber¬
ation of gastrin, and histamine representing the second final link".
Code (1956) proposed "no other chemostimu1ator is interpaired
between histamine and the parietal cell. Histamine is the final common
local chemo-stimulator of the parietal cells of the gastric mucosa".
This theory has been challenged (Grossman 1967; Johnson 1971) and more
recently, Soil (.1978) using isolated parietal cells has suggested that
histamine employs a permissive role in gastric secretion.
In 1937, Bovett and Straub demonstrated 2-isopropyl-5-methyl
phenoxyethyldiethylamine antagonised some of the actions of histamine
yet antagonism of other actions of histamine such as gastric secretion
were not affected. Other attempts to antagonise gastric secretion with,
conventional antihistamines all resulted in failure (Moersh, Rivers:,
and Marlock 19^6; Emmelin and Frost 19^7; Ashford, Heller and Smart
19^9; Doscherholmer 19^9).
Kay (1953) utilised the lack of effect of conventional antihista¬
mines on gastric secretion by using these compounds in combination
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with histamine to develop his augmented histamine test. Ash and Schild
(1966) suggested calling the effects of histamine antagonised by anti¬
histamines Hj effects, but it was not until 1972 that the receptor
was defined.
1.7 The introduction of Cimetidine. In 1972, Black and his colleagues
demonstrated that the first f^-receptor antagonist, buriamamide, inhib¬
ited histamine and pentagastrin stimulated gastric acid secretion by
57%. The absorption of the drug was found to be unreliable in experi¬
mental animals and no further evaluation of this compound was performed
in man. Slight alteration in the chemical structure of burimamide
resulted in a compound with improved solubility and ionisation, hence
providing better absorption. The resulting compound, metiamide, was
found to be more potent than burimamide in decreasing stimulated acid
secretion and reached the stage of clinical trials to assess healing
in duodenal ulceration.
Unfortunately, although it was shown to be efficacious in healing
duodenal ulcer, 7 cases of bone marrow depression were reported, one
of whom died (Burland, Sharpe, Colin-Jones, Turnbull and Bowskill, 1975).
Metiamide was, therefore, withdrawn from all further use in man.
Cimetidine was the third H^-receptor antagonist to be synthetfsed
and was found to be without side effects or adverse reactions i.n
experimental animals. It was shown to effectively inhibit all forms
of stimulated gastric acid secretion in man (Burland and Mills, 1979;
Longstreth, Go and Malagelada 1976; Carter, Forrest, Logan, Ansel 1,
Lidgard, Heading and Shearman, 1976; Pounder, Williams, Russell,
Milton-Thompson and Misiewicz 1976; Schoon and Olbe 1977) and numerous
clinical trials have confirmed its efficacy at both relieving symptoms
and healing duodenal ulceration (Bodemar and Walan 1976; Gray,
11.
McKenzie, Smith, Crean, and Gillespie 1977; Bardhan 1979).
Cimetidine dramatically altered the management of peptic ulcer
disease. For the first time, it was possible to effectively control
acid secretion over a prolonged period of time without resorting to
surgery. Cimetidine was introduced on the open market in the United
Kingdom in 1976 (Duncan and Parsons 1980), and in the United States in
1977. Since its introduction, over 15 million patients have been treated
worldwide, and in the United States an estimated 1 in 50 of the popu¬
lation have been given the drug (McGuigan 1981). Several other
receptor antagonists are at present under investigation and one of these,
ranitidine, has recently been introduced on open prescription in this
country.
Cimetidine was shown to be a relatively safe drug. In short term
clinical trials of 2,182 peptic ulcer patients, treatment with cimetidine
resulted in withdrawal of 2k (1.5%) patients because of untoward side
effects compared to 10 (1.2%) of 8kk patients treated with placebo
(Bur 1 and, 1978).
During the 20 years before the introduction of cimetidine, it had
been noted that there had been a steady decline in both hospital
admissions and mortality from peptic ulcer. This observation had been
made in this country (Coggan, Lambert and Langman 1981; Langman 1982)
and abroad (Fineberg and Pearlman 1981). This decline has been drama¬
tically accelerated by cimetidine. Venables (1980) reported that the
number of elective operations performed in his unit fell from 5k per
year before 1976 to 29 per year in 1977 ~ an overall reduction of k1%.
Other authors have reported a similar trend (Wyllie, Clark, Alexander-
Williams, Bell, Kennedy, Kirk and McKay 1981; Coggan, Lambert and
Langman 1981; Fineberg and Pearlman 1981). More recently however, it
has been recognised that not all patients benefit from these drugs
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and surgery is still required in some cases.
1.8 Medical treatment after cimetidine. Since the introduction of
cimetidine, there have been many clinical trials assessing new methods
of treatment. Most of these trials use cimetidine as a standard to assess
healing at it is now unethical to compare any new treatment with placebo
(Marks, Wright, Denyer, Garish and Luck 1980; Morgan, McAdam, Pacsoo,
Walker and Simmons 1978; Martin, Hollander, May, Ravenscroft, Tweedle
and Miller 1 981) .
As cimetidine provides healing rates around 75%, extremely large
numbers are required to show a statistically significant benefit using
other treatments. For example, if a new therapy was found to have a
healing rate as high as 20% above that of cimetidine in a trial of 10.0
patients, there would only be a 50% chance of this being significant at
the 5% level. Thus, it is extremely difficult to show any treatment is
superior to cimetidine.
As. more experience is gained with cimetidine, more side effects
are being noted. Mental confusion may occur in the elderly or very ill
in whom cimetidine may cross the blood brain barrier (Roley-Jones,
F1ind and Backhouse I980). Cimetidine has mild antiandrogenic effects
in animals in much higher doses than that which are used clinically
(Burland 1978). It causes an increase in serum prolactin when given
as an intravenous bolus in man and has been shown to elevate serum LH
and testosterone (Knigge, Wollesen, Dejgarrd, Thuesen and Christiansen
1981; Edwards and Rilley 1981). It also decreases the response of
aldosterone to angiotensin, inhibits vasopressin release and causes
an exaggerated response of TSH to a TRH stimulation test. Reported
side effects have included gynaecomastia, impotence and loss of libido
(Edwards and Rilley 1981). It has also been shown that cimetidine
interferes with hepatic metabolism of other drugs such as warfarin,
diazepam, phenytoin and antipyrine (Henry, MacDonald, Kitchingman, Bell
and Langman 1980; Serlin 1981; Babb. 1981). More recently there have
been reports of arthropathy (Committee of Safety of Medicines 1981a) and
renal failure (Payne, Ackrill and Ralston 1982) associated with cimeti-
dine therapy. Early experience with ranitidine suggests that the
latest H2~receptor antagonist is without most of these problems, although
two reports (Knigge, Wollensen, Dejgarrd, Thuesen and Christiansen
1981; Lombardo 1982) have shown an increase in serum prolactin with
ranitidine.
One of the most serious risks of cimetidine is the ability to
suppress the symptoms or even heal an early intramucosal gastric car¬
cinoma or lymphoma and thus delay diagnosis. Even an experienced
endoscopist can miss small lesions on the lesser curvature and it seems
likely that a missed carcinoma was present before cimetidine treatment
in all of the twenty-one patients with gastric carcinoma in association
with cimetidine treatment reported to the Committee of Safety of
Medicines up to January 1981 (Committee of Safety of Medicines 1981b).
A further association between cimetidine and gastric cancer has
been suggested by two hypothetical mechanisms. The first suggests
that by raising intragastric pH, colonisation of the stomach by nitrate
reducing bacteria might increase intragastric nitrite and subsequently
nitrosamines and nitrosamides which theoretically might be associated
with an increased risk of gastric carcinoma (Ruddell, Axon, Findlay
and Bartholomew 1980). Hunt, Vincent, Kelly, Perry and Milton-
Thompson (I98O), however, have shown that vagotomy is even more
effective at raising pH than cimetidine and Stalsberg and Taksdal
(1971) have shown a six-fold increase in the risk of gastric carcinoma
following gastric surgery. Moreover, recent work (Milton-Thompson
Lightfood, Ahmet, Hunt, Barnard, Bavl.n, Br imbl ecombe, Darkin, Moore
and Viney 1982; Muscroft, Youngs, Burdon and Kieghley 1981) casts
coubts on this theoretical risk hy showing that in normal subjects on a
normal diet, cimetidine lg/day does not alter pH sufficiently to pro¬
duce bacterial colonisation, nor are there any consistent changes in
nitrate reducing bacteria, nitrite or nitrosamine levels.
A more worrying hypothesis is that intragastric nitrite may combine
with cimetidine, resulting in n i't rosoc i'met id i'ne which is of similar
chemical structure to MNNG (N-methyl-N-ni troso-N-ni trosoguanidine), a
known potent gastric carcinogen in animals (Elder, Gangul i and
Gillespie 1979K Nitrosocimet i dine, however, has never been isolated
from the stomach in man. Many other drugs such as chlorpromazine,
chlordiezepoxide, tetracycline and oxytetracycline also undergo nitro-
sation producing theoretically carcinogenic metabolites yet malignancy
has not been reported in association with any of these drugs.
Despite these theoretical risks, cimetidine is probably the drug
of choice for duodenal ulcer at the present time.
1.9 The surgical treatment of duodenal "ulcer. The surgery of peptic
ulcer has changed considerably over the last century. Gastrectomy
became popular after Pean (1879) demonstrated this procedure was
technically possible. Unacceptably high morbidity and mortality, even
in experienced hands, resulted in the introduction of other alternatives
(Visik 1948).
Wofler, Bilroth's assistant, (1881) performed the first gastro¬
enterostomy for malignant disease and this soon replaced gastrectomy
in the treatment of duodenal ulcer. The first report of stomal
ulceration following gastroenterostomy appeared in 1899 (Braun) and
soon afterwards Mayo (1902) reported a 25% recurrence rate in a
15.
personal series of 102 gastroenterostomies.
Pavlov (1910) noted vagotomy decreased acid secretion in the dog,
and Laterjet (1921) suggested using vagotomy for treating duodenal ulcer.
Section of the vagus nerves in man was shown to decrease intragastric
acidity in 1929 (Hartzell), but it was left to Dragstedt and Owens
(19^3) to popularise the operation.
Laterjet had recommended a gastroenterostomy with vagotomy and
although at first Dragstedt and Owens (19^3) did not recommend drainage,
later reports (Dragstedt 19^5) suggested this could avoid problems with
stasis.
Colp (1950) was dissatisfied with high recurrence rates after
vagotomy and combined this procedure with antrectomy. Others found
diarrhoea and dumping unsatisfactory complications after vagotomy and
pylorplasty and introduced selective vagotomy (Griffiths and Harkins
(1957) and proximal gastric vagotomy (Amdrup and Jensen 1970; Amdrup,
Johnson and Goligher 1970; Johnston and Wilkinson 1970). Although
diarrhoea and dumping are less after proximal gastric vagotomy (Gillespie
1982), they are still recognised complications of this form of surgery
(Humphrey, Johnston, Walker, Pulvertaft and Goligher 1972) and some
authors report a 15~20% recurrent ulcer rate (Blackett and Johnston
1981; Venables I98O; Gillespie 1982).
As the treatment of choice, surgery carries unacceptable morbidity
and mortality and should, therefore, only be performed when indicated.
An operation is a relatively high price to pay for what is essentially
a benign disease characterised by only short exacerbations and prolonged
remissions. Indications for surgery included failed medical treatment
or complications such as bleeding, perforation and stenosis. Contra¬
indications include poor physical health and mild or infrequent attacks.
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CimetidIne has not altered these indications although may have decreased
their incidence.
In 1950, Colp wrote "in our experience less than 15? of patients
suffering from duodenal ulcer fail to respond either permanently or
temporarily to effective medical treatment". Although this figure was
not supported by any data, it is interesting to note that it is less
than the present estimates of those patients who do not respond to
blockade.
1.10. The clmetidine nonresponder. It is becoming increasingly recognised
that cimetidine will only heal between 57 and 87? of duodenal ulcers
after a six week course of therapy (Burland, Hunt, Mills, Milton-
Thompson 1977; Bardhan 1981). Although in most cases, continued treat¬
ment ultimately results in healing, the pattern of response is predictable
in that some 7 in every 100 patients with duodenal ulcer have more than
three attacks per year (Bardhan 1980).
Several questions need to be answered about patients who fail to
respond to cimetidine. Firstly, why do they not respond; secondly, is
any other medical therapy effective and finally, if surgery is indicated,
do these patients have a good result from vagotomy or should more
radical surgery be performed?
One possible explanation for nonresponse is poor compliance. Boyd,
Wilson and Wormsley (1982) have monitored compliance by counting tablets
and measuring drug metabolites in early morning urine samples. They
concluded that compliance did not differ between patients whose ulcer
remained healed and those who relapsed. This is not really surprising
because patients with active ulcer disease experience pain which gives
them an incentive to take their tablets.
Once symptoms disappear, compliance may not be important because
a recent study (Lance and Gazzard 1982) has shown that the number of
ulcers that can be shown to have endoscopica11y healed three months after
presentation, is independent of the length of treatment, as long as the
patients take their tablets until symptoms disappear.
Boyd, Wilson and Uormsley (1982) have also shown that patients who
relapse on maintenance therapy are no different from those who do not as
regards age, sex, duration of history, smoking habits and alcohol con¬
sumption. These findings have been confirmed by Bardhan (1981b) who
called the cimetidine resistant ulcer "refractory ulcer". Bardhan has
also shown no significant differences in -endoscopic features, acid and
pepsin outputs and serum gastrin levels when compared to non-refractory
ulcer patients (Bardhan 1981c).
Peden, Boyd and Wormsley (1981) found women less likely to heal
their ulcer but Sonnenberg and colleagues -(1981) found an increased
incidence of healing in women. They also found moderate alcohol intake,
abstinence from smoking and young age were good prognostic indicators
whereas concomitant disease, number and total area of peptic lesions,
family history and duration of history had no influence on whether the
ulcer responded to treatment.
Dragstedt (19^5) suggested that the most important aetiological
factor in the pathogenesis of duodenal ulcer was increased vagal drive
manifested by nocturnal hypersecretion. More recently, Hunt (1981) has
noted that although during the daytime, individual responses to cimetidine
are similar, overnight there are two patterns of response; one group
of patients show little or no decrease in hydrogen ion acitivity when
receiving cimetidine, whereas a second group become relatively anacidic.
When looked at retrospectively, the former group of patients were noted
to have a poor response to treatment.
There have been two reports of increased basal acid output in
cimetidine nonresponders (Hetzel, Hansky, Shearman, Korman, Hecher,
Taggart, Jackson and Gahb, 1978; Cargill, Peden, Saunders and Wormsley
1978) but Longstreth and Malagdelada (1976)1 found spontaneous rate of
acid secretion was of no value in predicting response to the drug.
Binder and colleagues (1978) recorded increased peak acid output after
betazole in nonresponders and Hetzel, Hansky, Shearman, Korman, Hecher,
Taggart, Jackson and Gabb (1978) noted increased peak acid output after
pentagastrin although did not find this significant. Others (.Hunt, 1281
Boyd, Wilson and Wormsley 1981; Bardhan 1981b) have not found increased
basal or peak acid outputs in nonresponders.
Kirkpatrick and Hirschowitz (1980) reported 12 hypersecreting duo¬
denal ulcer patients whose basal acid output was resistant to cimetidine
therapy, but decreased by 90% with atropine, inferring cholinergic
drive. A group of duodenal ulcer patients with a high basal acid out¬
put which did not greatly increase with sham feeding made Feldman,
Richardson and Fordtran (1980) conclude that some patients have incre¬
ased vagal drive although did not relate this with nonresponse to
cimetidine.
Venables (1980) using a combined pentagastrin/insu1in test has
shown that after insulin stimulation, the usual relationship between
acid and pepsin secretion is lost in those who heal. This led him to
suppose that patients who fail to heal are more responsive to vagal
stimulation than those who do heal. This suggestion is also supported
hy his finding that in ten patients who failed to respond, after
randomly receiving either cimetidine and an anticholinergic agent or
cimetidine alone, all on the combined therapy healed their ulcer
compared to three out of five taking cimetidine alone. Thjodleifsson
and Wormsley (1975) have also suggested that when nocturnal acidity
is not controlled by H^-receptor blockade, the degree of gastric
inhibition can be increased by atropine, and this observation has
been confirmed by others (Thompson, Albinus, Blair, Reed, Venables 1975;
Barbezat and Banks 1976). Combination of cimetidine with a new locally
acting antimuscarin?c agent, pirenzepine, has resulted in better acid
inhibition than cimetidine alone (Londong, Londong, Weber and VonWerder
1980). The combination has also been shown to improve healing rates of
duodenal ulcer compared to either drug used alone (Roberto, Nicola and
Sergio 1982) .
Increased vagal drive when receiving cimetidine is suggested by the
findings of Maybury and Cari—Locke (1980) in that a high relapse rate
may be predicted if an insulin test produces the same acid response when
receiving cimetidine as when receiving no drug at all.
Vagal stimulation in patients with active duodenal ulcer produces
a greater increase in pepsin output than acid output (Roland, Berstad,
and Liavag 197^; Clarke, Allan, and Alexander-Williams, 1972; Rosato
and McFadyen 1971), and measuring basal pepsin output should be a better
indicator of increased vagal drive. Japanese workers (Kishi, Seki,
Kilamura and Mori 1978) have found an increased intragastric basal pepsin
output and Pikkarainen, Vuoristo and Torpila (1981) found increased serum
pepsinogens in patients with ulcers which fail to heal, although Wormsley
(1981) and Bardhan (1982) have found no increase in pepsin output in
cimetidine nonresponders.
The hypothesis that increased vagal drive results in nonresponse
to blockade is supported by the results of vagotomy. Hypersecretfng
duodenal ulcer patients described by Kirkpatrick and Hirschowitz (1980)
had very good results from vagotomy, as did three patients who met the
criteria of nonresponse to cimetidine reported by Hunt et al (Hunt,
Vincent, Kelly, Perry and Milton-Thompson I98O). Venables (1980) has
reported a 16.6% recurrence rate in nonresponders after proximal
gastric vagotomy (PGV) compared to a 5% recurrence rate with truncal
vagotomy and pylorplasty before the introduction of cimetidine. This
high recurrence rate, however, is similar to a 16% recurrence rate with
proximal gastric vagotomy in cimetidine failures reported by Blackett,
and Johnson (1 981) : t h i s compared with ]k% before cimetidine using the
same operation. These high recurrence rates in nonresponders may be due
to more accurate diagnosis with the widespread use of endoscopy to
document recurrence rather than poor results with highly selective
vagotomy.
Before deciding how to evaluate cimetidine nonresponders, it is
necessary to discuss the functions of the stomach and the different
investigative options.
1.11 The functions of the stomach. These can be broadly divided into
motility and secretion. Motility is mainly assessed by measuring the
rate of gastric emptying. Several methods are employed using either
the dye dilution technique (George 1968) or more commonly radioactive
test meals (Griffith, Owen, Kirkman and Shields 1966). Both these
methods are fraught with difficulties. The dye dilution technique
only measures emptying of liquids and involves the passage of a naso¬
gastric tube which is not physiological. Rate of emptying depends on
not only the position of the patient (Hancock, Bowen-Jones, Dixon,
Testat, Dymock and Cowley 197*0 but also on the type of marker used;
different rates are reported between liquids and solids (Heading,
Tothill, McLoughlin and Shearman 1976) and between water soluble and
fat soluble markers (Cortot, Phillips and Malagelada 1981). Although
Kirkpatrick and Hirschowitz have noted a higher residual volume in
nonresponders (Kirkpatrick and Hirschowitz 1980) which they thought
might be due to delay in gastric emptying, this thesis has not inves¬
tigated gastric emptying because of the difficulties with interpretation.
Leube (1868) was the first to suggest the possibility of studying
gastric physiology by aspiration of the stomach contents. Although this
method has the disadvantages of being unphysio1ogica1 and unpleasant for
the subject, it is still the best method of obtaining information about
gastric secretion.
The stomach secretes acid, pepsin, water, mucus and bicarbonate, all
of which have been measured: in a basal state either in the fasted patient
(Galambos 1926; Levin, Kirsner and Palmer 1951), overnight (Wi'nkel stei'n
1935;) or over a twenty-four hour period (Voegt1in 19**7; Pounder, Williams,
Milton-Thompson and Misiewicz 1976) in a stimulated state using either
histaminic (Kay 1953), gastriergic (Wormsley, Mahoney and Ng 1966) or
cholinergic stimuli (Wilson, Dymock and Cowley 197*0. or a combination of
these using food (Von Leube 1871; Fordtran and Walsh 1973); or in an
inhibited state employing histamine H^-receptor antagonists or anti-
cholinergics.
Acidity is measured by recording pH using a glass electrode (Moore
and Scarlata 1965) and total free acid is measured after titrating a
sample of gastric juice to pH7 with sodium hydroxide using an autobur-
ette (.Radiometer, Copenhagen) and dividing the number of moles of
alkali added by the volume of juice sample. If this figure is then
multiplied by the total volume of juice over a given time, total acid
output is calculated.
Pepsin is usually measured by the Anson and Mirsky method (.1932)
which utilizes the digestive properties of pepsin. A known amount of
haemoglobin is incubated with gastric jui.ce and after digestion over
a period of time, any colour change is measured col orimetrica11y.
When this reading is compared to a known standard amount of crystalline
pepsin, a value can be obtained. Methods have evolved to improve the
substrate using modified haemoglobin (Berstad 1970) or radioactive
iodinated albumin (Klofz and Duval 1 19J>7)_, but all methods suffer from
the disadvantage of being time consuming and not always reproducible
because of the variable purity of commercially available pepsin.
Bicarbonate may be measured by utilizing various markers with gas¬
tric and duodenal tubes (Rees and Turnberg 1981). Numerous calculations
are made to allow for pyloric loss and reflux but these obviously de¬
crease the accuracy of the technique. Two nasogastric tubes are also
uncomfortable for patients. Similar sophisticated methods are used to
measure gastric mucus (Glass 1967; Horowitz 1967) and techniques have
evolved to calculate mucoprotective index but these also involve complex
calculations (Guslandi, Testori, Fesce, Ballarin and Tittobello 1980).
The main thrust of research into gastric secretion has been dir¬
ected at acid secretion although even this is not without difficulties.
Saliva dilutes gastric juice, secretions are lost via the pylorus and
bile refluxes into the stomach so neutralising acid.
Various techniques exist for positioning nasogastric tubes (Hassan
and Hobsley 1970) and also for correcting for reflux (Gardham, Hassan
and Hobsley 1968) and for pyloric loss using either XI31 (Johnston
1958) or phenol red (Hobsley and Silen 1969; Hassan, Gardham and Hobsley
1969; Venables 1972). However, these techniques only improve collec¬
tions by 5% (Hobsley and Silen 1969) , and it has been reported that
a 98% recovery can be expected using a combination of continuous
suction by a mechanical pump interrupted by manual aspiration (Johnston
and McGraw 1958). One report (Cook and French 1968) also suggests
that phenol red is absorbed from an acid stomach and previous personal
experience has found the method to be messy and not always reliable.
The main problem of using phenol red is that the standard nasogastric
tube has to be modified by the addition of an extra lumen which should
be brought to the outside 15 cm from the tip. This often produces
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damage to the tube, so producing an imperfect vacuum for aspirating
gastric juice and also sometimes giving the investigator difficulty in
passing the tube.
Collection techniques are more accurate if large volumes of secretion
are collected (Hassan, Gardham and Hobsley 1969), and as nonresponders
have been reported to have large volumes of secretion (Hetzel, Hansky,
Shearman, Korman, Hecker, Taggart, Jackson, Gabb 1978; Cargill, Peden,
Saunders and Wormsley 1978), studies in this thesis have not utilized
a marker.
1.12 Conclusion. The previous review of the literature suggests that
there may be several reasons for nonresponse to cimetidine but increased
vagal drive appears to be of particular importance. Dragstedt 09^5,
) has suggested that increased vagal tone is manifest by nocturnal
hypersecretion and it was, therefore, decided to first investigate
secretion during the overnight period. The night time was also felt to
be of particular importance because Hunt (1982) had observed a distinct
difference between responders and nonresponders during the night but
not during the day. The initial studies in this thesis, therefore,
looked at nocturnal gastric secretion in nonresponders compared to a
group of duodenal ulcer patients who had been studied previously at
the Royal Naval Hospital, but who were not selected as being a respon-
der or nonresponder. The first studies also investigated how nocturnal
secretion was modified by an increased dose of cimetidine^by combination
of cimetidine with atropine and by surgery.





2.1 Patients. Any criteria chosen to define a nonresponders must be
done arbitarily. Continued treatment with cimetidine improves the numbe
of ulcers which heal (Bardhan 1980) and, therefore a specific period of
treatment must be defined.
It is also known that relapse on maintenance therapy is higher than
on full dose treatment (Pounder 1981; Bardhan 1981) and therefore a dose
of treatment must also be defined. Cimetidine may relieve symptoms with
out healing the ulcer (Bardhan 1981b) and some patients who stop treat¬
ment, relapse early because their ulcer was not healed. There will often
be a delay in diagnosing relapse in these patients because they may
either delay in reporting symptoms or endoscopy may be delayed because
of hospital waiting lists. The criteria chosen for a cimetidine non-
responder in this thesis included:
1) Failure to heal after cimetidine lg/day for 6 weeks
2) Relapse on maintenance therapy of AOOmg nocte
3) Relapse within a month of stopping cimetidine lg/day
for 6 weeks
Other groups studied in this thesis are referred to as either:
a) Normal subjects. These are healthy volunteers who have no clinical
evidence of any disease and who are not receiving any form of
medical therapy other than was administered during studies.
b) Unsebcted duodenal ulcer patients. These are a group of patients
with an endoscopica11y proven duodenal ulcer who were studied
previously at the Royal Naval Hospital, Haslar under identical
conditions, but who were not selected by criteria of nonresponse
and, therefore, this group contains both responders and nonrespon¬
ders .
c) Responder duodenal ulcer patients. These patients have had an
endoscopica11y proven duodenal ulcer which has responded to
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treatment and no longer gives, symptoms one month after stopping
treatment. Most of this group had endoscopy performed to show
healing, but this was not so in every case and therefore this group
probably contained a small number of asymptomatic ulcers.
All duodenal ulcer patients studied in this thesis had no clinical
evidence of any cardiac, respiratory, renal, hepatic, endocrine, neuro¬
logical or other gastroenterological disease. Any patient with a con¬
comitant gastric ulcer was excluded from the studies, as was any patient
taking any form of medical therapy other than for his duodenal ulcer.
Prior to each study, all ulcer medications were withdrawn for 2b hours.
Only male subjects and patients were studied because only one
Nightingale Ward was available which was not equipped with facilities
for both sexes. In addition, most of the personnel available as volun¬
teers from Haslar were male subjects as were most of the Naval patients.
All patients and subjects gave their informed consent to all the
studies in accordance with the Declaration of Helsinki. All studies
were performed to a written protocol which had prior approval by the
Royal Naval Hospital Ethical Committee.
2.2 Statistical Methods. All pH measurements have been converted to
hydrogen ion (H+) activity for statistical analysis.
Comparison of results was done by paired Student "t" test when
looking at mean values in the same patients receiving different treat¬
ments and by unpaired "t" test when compairing mean values in different
groups of patients receiving identical treatments.
All data was stored on a Hewlett Packard System b5 desk top com¬
puter, and all calculations performed by this computer after consultation
with the statistics department of the Royal Naval Hospital, Haslar.
Data was judged to be significant if calculations showed findings
to be of less than 5% probability (p<0.05).
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2.3 The twenty-four hour study. The twenty-four study has been used
as a standardised technique at Haslar since Pounder, Williams, Milton-
Thompson and Misiewicz (1975) first used the method during the initial
investigation of cimetidine. During their studies, they checked the
reproducibility of the technique by using a placebo regimen on two
separate occasions which resulted in a good correlation (r=0.80; p<0.01).
The methods used since have been performed to an identical protocol.
Most studies in this thesis used a standard twenty-four hour pro¬
tocol with different patients receiving a different treatment on each
occasion, A minimum of one week was allowed between each study day,
Patients fasted from midnight and attended a specially allocated ward
at 0730. A size 10 French Salem sump nasogastric tube (Argyl Labora¬
tories) was passed and position checked by water aspiration. Through¬
out the 2k hour period, pH was measured hourly using a glass electrode,
previously calibrated with buffers of pH k.O and 7.0 before each batch
of measurements.
The standard diet for each study day is shown in Table 2.1 and
was. estimated to contain approximately 2,960 calories, l44g of protein,
l43g of fat, and 2^8g of carbohydrate. Patients were encouraged to
lead a normal life, eat their meals at a table and entertain themselves
with games such as cards, dominoes or watching television. The number
of cigarettes and ad lib drinks were recorded on a data sheet and
repeated on subsequent occasions by reference to the records.
At 0100 the stomach was emptied by manual suction and continu¬
ous mechanical aspiration at -50mm Hg used overnight to collect
gastric secretion. Mechanical suction was interrupted by supple¬
mentary manual aspiration every 20 minutes and a small quantity of
air blown down the tube to ensure patency.
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Overnight, volume of gastric secretion was recorded hourly and a
5ml sample of gastric juice taken for titration to pH 7.0 with 0.1
molar sodium hydroxide using an autoburette (Radiometer Copenhagen).
From these readings, acid output was calculated.
All cimetidine tablets and injections and the intravenous impro-
midine were supplied by Smith, Kline and French Laboratories, Welwyn
Garden, Herts; and ranitidine was supplied by Glaxo Group Research, Ware,
Herts. All other drugs were supplied by the Pharmacy, RN Hospital,
Hasla r.
2.3.1 The effect of cimetidine ig/day and 2g/day. Twelve nonresponders
mean age 33 years (range 20-53) were studied over three separate 2k
hour periods receiving either no treatment, cimetidine 200mg tds with
food and ^OOrng nocte (lg/day) or cimetidine AOOmg tds with food and
800mg nocte. Any sample of gastric juice taken within two hours of
drug administration was returned to the stomach.
As the overnight period was of particular importance, passing the
nasogastric tube was delayed until 1500. This allowed the patients to
eat two of their three main meals without the inconvenience of a naso¬
gastric tube. Otherwise the standard protocol as described in the
preceding section was used. The basic design is shown in Figure 2.1.
On attending the ward at 0730, a fasting serum was taken and stored
at -20°C for later gastrin estimation using a radioimmune assay.
The nocte dose of cimetidine was adminstered at 2200. At 2130,
a 19 gauge butterfly was inserted into a forearm vein and kept patent
with heparinised saline. Blood was taken at 2130, 2200, 223Q, 2300,
2330, 2A00, 0100, 0200, 0^00, and 0600, spun down at 5,000 revolutions
per minute and the serum stored at -20°C for later estimation of serum
cimetidine using high pressure liquid chromatography. This technique
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involves extracting the cimetidine using octanol. After a water-wash,
back, extraction into acid and salting out with sodium bicarbonate, the
samples were injected as an alcoholic solution onto a Lycrosorb column
using acetonitrile as a solvent. After approximately 20 minutes reten¬
tion, cimetidine was detected at an ultraviolet range of 228-230 nm.
The serum cimetidine results were compared to a previously reported
study using eight healthy volunteers (Heading, Tothill, McLoughlin,
Shearman, 1976.)
2,3.2 The effect of cimetidine in nonresponders compared with, an
unselected duodenal ulcer population. Dr. Richard Hunt kindly
made available data from 25 duodenal ulcer patients who had been stud¬
ied under an identical twenty-four hour protocol as the previous
chapter. This group were not selected by criteria of nonresponse, but
all had an endoscopica1 1 y healed duodenal ulcer. To compare these
previous results with nonresponders, it was decided to study a further
13 nonresponders over two separate 2k hour periods receiving either no
treatment or cimetidine lg/day. When combined with the results of the
no treatment day and the cimetidine lg/day study in the preceding
section, a total of 25 nonresponders mean age 33 years (range 19~53)
were available for comparison with the unselected duodenal ulcer
patients.
It was felt at the start of this experiment that if any abnormal
responses were observed, further investigation might include measuring
overnight hormone levels. As a safety measure therefore^ blood was
taken at 2030, 2130, 2230, 2A00, 0200, 0A00, and 0600 via a 19 gauge
butterfly cannula (previously inserted into a forearm vein) kept
patent with heparinised saline. Before aspirating samples, 2mls. of
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the hormone assay. In order to prevent inactivation of some hormones,
blood was placed in a sequestrene tube prepared by the addition of
trasylol. The samples were then spun down and the supernatant placed in
a glass tube and immediately frozen at -20°C for storage.
2.3.3 The effect of cimetidine Ig/day combined with atropine 2,Amg/day.
Eleven nonresponders mean age 32.1 years (range 20-^5) and mean weight
73.3 kg (range 68-80) were studied over three separate 2k hour periods
receiving either no treatment, cimetidine lg/day or cimetidine Ig/day
with atropine 2.4mg/day taken in four divided dosos with food. Again,
as the overnight period that was of particular interest, the naso¬
gastric tube was passed at 1500. Otherwise, the protocol was as prev¬
iously described in 2.3.1.
2.3.4 The effect of highly selective vagotomy. Ten nonresponders mean
age 34.5 years (range 24-50) who had frequent severe relapses, not
controlled by other medical measures were studies over two 2k hour
periods receiving either no treatment or cimetidine lg/day. Gastric
juice was only sampled from 1500.
After the two study days, all the patients were referred for surgery
and all had a highly selective vagotomy without complications. Six
months post surgery, all had a history and examination, insulin test
and repeat 2k hour study. The clinical assessment was to determine
the Visik classification (Visik 19^8), the insulin test to determine
whether a complete vagotomy had been performed and the 2k hour study
to compare the effect of surgery with that of cimetidine.
For the insulin test, patients fasted from midnight and attended
the ward at 0730. A size 14 French Salem sump nasogastric tube
(Shearman Laboratories) was passed and position checked by water aspir¬
ation. The stomach was emptied by manual suction and continuous
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mechanical aspiration performed at -50mm of mercury, supplemented by
intermittent manual aspiration every 5 minutes to improve the accuracy
of the collection technique (Baron 1978)". Gastric secretion was collec¬
ted every 10 minutes, volume measured, pH recorded and a 5ml sample
titrated to pH 7 to calculate acid output. Samples were collected for
a half-hour basal period and basal acid output expressed in mmol/hr
after calculating the sum of the three ten minute values multiplied by
two. A subcutaneous injection of insulin 0.2 units/kg was then given
and gastric juice collected for a further 120 minutes. Peak acid out¬
put experessed in mmol/hr was calculated by~ the sum of the highest
three consecutive ten minute collections multiplied by two.
CHAPTER 3
RESULTS
3.1 The effect of cimetidine lg/day and cljnetidine 2g/day. All patients
tolerated the experiment well. Mean nocturnal hydrogen ion activity
decreased from 45 mmol/1 on no treatment to 33 mmol/1 with cimetidine
lg/day (p< 0.05) and to 31 mmol/1 with cimetidine 2g/day (p< 0.05 com¬
pared with no treatment and not significant compared with the lg dose)_.
Mean hourly variation isshown in Figure 3.1.1.
Mean nocturnal volume (Figure 3.1.2) decreased from 8lml/hr on no
treatment to 64ml/hr with cimetidine lg/day (not significant) and to
54ml/hr with cimetidine 2g/day (not signi"ficiant when compared with
either no treatment or cimetidine lg/day)„.
Mean nocturnal acid output (Figure 3.1.31 decreased by 41% with
cimetidine Ig/day (p< 0.05) and by 51% wi tli cimet id ine 2g/day (p<0„05
compared with no treatment and not significant compared with lg dose).
Serum cimetidine levels are shown in Figure 3.1.4. Absorption of
cimetidine in the nonresponders is no different from the normal subjects
after a 400mg nocte dose. Doubling the dose of drug resulted in doubling
of the peak serum level. Thus, despite adequate absorption, increasing
the dose of cimetidine did not improve response.
3.2 The effect of cimetidine on nonresponders compared with an
unselected duodenal ulcer population. All patients tolerated
the study well. Mean nocturnal hydrogen ion activity is shown in
Figure 3.2.1. On no treatment there was no signficant difference be¬
tween the nonresponders and the unselected duodenal ulcer patients
(49 mmol/1 and 48 mmol/1 respectively). After cimetidine lg/day, mean
nocturnal hydrogen ion activity decreased to 33 mmol/1 in the nonres¬
ponders (p< 0.05) and to 12 mmol/1 in the unselected duodenal ulcer
patients (p< 0.001 compared with this group on no treatment and
p< 0.01 compared with the nonresponders on cimetidine).
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Volume of gastric secretion is shown in Figure 3.2.2. When on no
treatment, there was no significant difference between the mean nocturnal
volume of gastric secretion of the nonresponders and the unselected duo¬
denal ulcer patients (7Aml/hr and 55ml/hr respectively). After cimetidine
lg/day, volume decreased to 56ml/hr in the nonresponders (not significant)
and to 29ml/hr in the unselected duodenal ulcer patients (p< 0.01 com¬
pared with the nonresponders on cimetidi'ne.
Acid output is shown in Figure 3.2.3. There was no significant
difference between the mean nocturnal acid output of the nonresponders
and the unselected duodenal ulcer patients when on no treatment (6.6
mmol/hr and A.3 mmol/hr respectively). After cimetidine Ig/day, acid
output decreased to 3.5 mmol/hr in the nonresponders (p< 0.05) and to
0.68 mmol/hr in the unselected duodenal ulcer patients (p< 0.001 com¬
pared with this group on no treatment and p< 0.01 compared with the
nonresponders on cimetidine).
Fasting serum gastrin was measured in 13 nonresponders - four of
these had mildly elevated levels at 9k, 92, 73 and 73 picog/1. The
mean value for all thirteen was 58.2 picog/1 (normal range 30-60).
Thus, nonresponse is associated with a decreased effect on acidity
levels and acid output, and a total absence of any significant effect
on the volume of gastric secretion during the overnight period and
serum gastrin levels are not grossly abnormal.
3.3 The effect ofcimetidinelg/day combined with atropine 2.Amg/day.
All patients tolerated the experiment well although one subject comp¬
lained of a dry mouth on the combination therapy.
Mean nocturnal hydrogen ion activity (Figure 3.3.1) decreased from
kS mmol/1 on placebo to 31 mmol/hr on cimetidine (p< 0.05) and to
29 mmol/1 on the combination (p< 0.05 compared with placebo and not
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significant compared with ci.metfdine alone).
Volume of gastric secretion decreased from 73m1/hr on placebo to
60ml/hr on cimetidine (NS) and to 52ml/hr on the combination (NS compared
with placebo and NS compared with cimetidine alone). (Figure 3.3.2).
Mean nocturnal acid output is shown in Figure 3.3.4. On placebo,
acid output was 7.3 mmol/hr compared to 4.3 mmol/hr after cimetidine
(p< 0.05) and 3.6 mmol/hr after the combination (p< 0.05 compared with
placebo and NS compared with cimetidine alone).
Thus, adding atropine 2-4mg/day does not improve response.
3=4 The effect of proximal gastric vagotomy. All subjects were graded
Visik I or II post surgery and all had a complete vagotomy by all the
previously reported criteria of : 1) No rise in acid concentration
of 20mEq/l or 10mEq/l above basal concentration (Hollander 1946); 2)
No rise of 0.25mEq in acid output in any hour (Stempien 1962); 3) Basal
acid output of less than 2mEq/hr or no increase of more than IraEq/hr
(Bachrach 1962).
Mean nocturnal intragastric H+ activity decreased from 41.1 -h 23.2
mmol/1 on no treatment to 27.30 +_ 35.38 mmol/1 with cimetidine (NS)
and to 14.47 +17.89 mmol/1 six months after surgery (p< 0.01). Figure
3.4.1 shows the mean hourly values.
Volume of gastric secretion decreased from 43.6 + 37.03 ml/hr on
no treatment to 42.18 +_ 25.95 ml/hr with cimetidine (NS) and to 17.62 +_
17.47 ml/hr six months after surgery (p<0.05 compared to cimetidine and
p< 0.01 compared to no treatment). The results are expressed in
Figure 3.4.2.
Acid output overnight decreased from 3.29 + 3.06 mmol/hr on no
treatment to 1.89 + 2.08 mmol/hr with cimetidine (p<0.05) and to 0.95
+ 1.22 mmol/hr six months after surgery (p<0.05 compared with cimetidine
and p< 0.01 compared with the no treatment regimen). These results are
shown in Figure 3.4.3=
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These results show that in nonresponders, vagotomy is superior to
cimetidine lg/day at decreasing intragastric acidity, volume of secretion





4.1 The effect of cimetidine lg/day and "2g/day. The aim of this study
was to see if nonresponse was related to poor drug absorption and to
assess whether increasing the dose of cimetidine would be expected to
improve response. The results suggest that cimetidine is adequately
absorbed in nonresponders and doubling the dose does not improve res¬
ponse despite a corresponding increase in peak serum level of drug.
The lack of benefit with larger dose agrees with a report that in
duodenal ulcer patients, acid secretion is inhibited by a similar degree
with either cimetidine 400mg nocte or cimetidine 800mg nocte (Blackwood
and Northfield 1977). Similar healing rates are reported comparing
0„8mg/day with lg/day (Peter, Fritsch, Nieschlag, Wienbeck and
Strohmeyer, 1977; Kerr 1981), l„2g/day (Blackwood, Maugdal, Pickard,
Lawrence and Northfield 1976), l„6g/day (Bodemar 1977; Blackwood,
Maugdal, Pickard, Lawrence and Northfield 1976) and 2g/day (Bardhan
1981).
Binder, Cocco Crossley et al (1978) showed less complete acid
inhibition with higher acid secretory rates. They hypothesised that
higher doses of cimetidine may be necessary in patients with higher
rates of acid secretion. Pounder, Williams, Hunt, Vincent, Milton-
Thompson, MIsiewicz (1977) found up to a maximum level, the degree of
acid inhibition was closely related to cimetidine blood levels sugges¬
ting that poor acid control is associated with low serum drug levels.
However, others have reported a poor correlation between drug levels
and acid inhibition (Cohen, Siepler, Nation, Bombeck, Nyhus 1980) and
that differences in clinical and endoscopic healing rates cannot be
explained by differences in pharmacokinetics between patients (Webster,
Petrie, Griffiths 1980). The results of this experiment would agree
with this latter suggestion.
Although prolonging treatment with cimetidine, results in
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increasing the number of ulcers which heal (Bardhan 1980), increasing
the dose of therapy is unlikely to increase the inhibition of acid
secretion and will, therefore, probably not be of clinical benefit.
b.2 The effect of cimetidine on nonresponders compared to an unselected
duodenal ulcer population. The aim of this study was to identify if non-
responders were different from other duodenal ulcer patients and compare
their response to cimetidine.
The result demonstrates that nonresponders do not differ signific¬
antly from the unselested duodenal ulcer patients with regard to noc¬
turnal acidity levels, acid output or volume of gastric secretion
although the latter two parameters were slightly increased in the non¬
responders .
Two previous reports have shown an increased basal acid output in
cimetidine nonresponders (Cargil, Peden, Saunders, Wormsley 1978; Hetzel ,
Hansky, Shearman, Korman, Hecher, Taggart, Jackson, Gabb 1978), but both
these reports were on fasted patients studied over a one hour period.
This method of measuring basal acid output is unreliable (Baron 1980).
One of the main problems is that it is never certain whether the stomach
is fully emptied before collections start. Kirkpatrick and Hirschowitz
(1980) noted a high residual volume in cimetidine nonresponders which
they thought might be related to delayed gastric emptying. Thus, incom¬
plete emptying of the stomach, which would give a falsely high value of
basal acid output, is more likely if residual volume is large. Most other
studies are in agreement that basal acid output in nonresponders is no
different from other duodenal ulcer patients (Hunt 1981; Boyd, Wilson,
Wormsley 1981; Bardhan 1981).
The present study suggests that serum gastrins are not grossly
elevated in nonresponders. Although patients with Zollingei Ellison
syndrome relapse early after stopping cimetidine, and their symptoms
are not always controlled by the recommended dose, this is an extremely
...56
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rare form of nonresponse (Bianchi and Quatrini 1980).
The study also demonstrates that nonresponse is associated with a
decreased effect of cimetidine at reducing nocturnal acidity and acid out¬
put together with a total abscence of any significant effect on the volume
of gastric secretion in cimetidine nonresponders. These findings together
with those showing adequate drug absorption in 3.1 , suggest that these
patients are resistant to the pharma1ogica1 effect of cimetidine and
that noncompliance is unlikely to be a main cause of nonresponse as has
already been demonstrated by Boyd, Wilson and Wormsley (1981). The
decreased effect of cimetidine in reducing H+activity has also been
observed by Hunt (1981).
There are several explanations for these findings. Nonresponders
might be at the poor response end of the normal therapeutic response
curve, however, the observation of no significant reduction of volume
of gastric secretion in contrast to the significant reduction in acid
output and hydrogen ion activity suggest some other mechanism is
involved.
One hypothesis is that cimetidine can only decrease acid secretion
by a defined amount in individual patients. However, although H+
activity, acid output and volume were similar in the two groups on no
treatment, after cimetidine, decreases of hydrogen ion activity, acid
output and volume in the unselected duodenal ulcer patients were all
much greater than the decreases in the nonresponders.
Duodenal ulcer may be the result of increased vagal drive
(Dragstedt 19^5) and Fritsch, Scholten, Muller and Hengels (I98O)
have shown that the more acid secretion is sensitive to vagal stimu¬
lation, the less the effect of histamine H2-receptor antagonists.
Many of the cimetidine nonresponders might have relapsed early and the
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observations may have been made on disease activity. This is. difficult
to disprove unless weekly endoscopy is performed which is obviously not
practicable. At the start of the studies, all patients were in remiss¬
ion and if the observations are related to disease activity, cimetidine
would be unlikely to promote ulcer healfng jn any patients.
Another explanation f«5r the observation of lack of effect on volume
is that collection techniques were poor in the nonresponders. The
techniques certainly have limitations but they were no different from
those used for the unselected duodenal ulcer patients, and any Inaccur¬
acies should have balanced out. The techniques have not been changed
at Haslar since the original studies by Pounder, Williams, Milton-
Thompson and Misiewicz (1975), all of which showed cimetidine to decrease
volume of gastric secretion in other duodenal ulcer patients. The
present experiment was conducted alongside other studies (G1 edhill,
Mills, Clancy, Buck, Hunt, Burland 1982) which used the same collec¬
tion techniques yet demonstrated a reduction in volume with cimetidine.
Residual volume has been reported to be increased in cimetidine non¬
responders (Kirkpatrick and Hirschowitz 1980) and it is possible that
the stomach was not emptied properly before overnight collections were
started. If this were true, nonresponders would have been expected
to have increased volume of secretion when reciving no treatment com¬
pared to the unselected duodenal ulcer patients, and this we did not
observe. In addition, great care was taken to ensure the stomach was
properly emptied before overnight collections.
Cimetidine may increase reflux and may have explained the lack of
effect on volume. Few samples however were noted to be bile stained
and if reflux had increased, the lack of effect on volume should have
also been noted in the unselected duodenal ulcer patients. It may
have been that reflux increases with cimetidine only in nonresponders.
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This might be a reason for nonresponse in gastric ulcer, but i.t is
unlikely to he a cause of nonresponse in duodenal .ulcer.
A further explanation for the lack of effect on volume is. that
cimetidine may have no effect on cholinergic pathways in nonresponders.
The review of the literature in the introductory chapter points to
increased vagal drive as a cause of nonresponse but if this were the
case, nonresponders should have increased volume of gastric secretion
when receiving no treatment. However, although a slight increase was
observed, this was not significant. The other possibility is that
cimetidine causes increased vagal drive. For this to occur, a hypo¬
thesis must be made that histamine inhibits vagal tone and treatment
with an H2-receptor antagonist stops vagal inhibition. This theory
is supported by the findings of Maybury and Carr-Locke (1980) who
found that cimetidine had no effect on insulin induced acid secretion
in patients who were resistant to cimetidine treatment.
If increased vagal drive leads to nonresponse, acid should be
controlled better by combining cimetidine with an anticholinergic
agent. The next study, therefore, measured the effect of cimetidine
comhined with atropine 2.Amg/day on acid secretion in nonresponders.
A.2.3 The effect of cimetidine lg/day in combination with atropine
~~ 2.Amg/day. This study demonstrated that cimetidine had a
decreased effect on nocturnal hydrogen ion activity and acid output
but no significant effect on volume of gastric secretion. The addition
of atropine gave no added benefit. Volume of gastric secretion is
thought to be predominantly under cholinergic control (Kirkpatrick,
Hirsehowrtz 1980) and, therefore, adding an anticholinergic agent
would seem a reasonable idea. Other authors have suggested combining




Previous reports on combination therapy are variable. Pounder,
Hunt, Vincent, Milton-Thompson and Misiewlcz (.1977) found no additional
benefit from atropine 2.4mg/day and Blackwood and Northfield (1977)
found adding poldine did not improve response. Thjod1eifsson and Wormsley
(197*0 and Barbezat and Bank (1976) suggested adding atropine provided
better control of acid secretion, and Venables (1980) suggested benefit
by adding poldine. Londong, Loncbng , V/eber and VanWerder (1980.) also
found improved response from adding pirenzepine.
The addition of an anticholinergic agent therefore does not always
improve control of acid secretion. To investigate vagal tone further,
the next study measured acid secretion in nonresponders after proximal
gastric vagotomy.
4.2.4 Proximal Gastric Vagotomy. The result repeated the earlier finding
that cimetidine had no significant effect on volume of gastric secretion
in cimetidine nonresponders. However, vagotomy produced significantly
better decreases in nocturnal hydrogen ion activity, acid output and
volume compared with cimetidine.
The result agrees with Hunt, Vincent, Kelly, Perry, Milton-Thompson
(1980) who found vagotomy decreased hydrogen ion activity better than
cimetidine in cimetidine resistant patients. Pounder, Williams, Hunt,
Vincent, Milton-Thompson and Misiewicz (1977) however, found vagotomy
produced an equal decrease in hydrogen ion activity to that produced by
cimetidine but they studied unselected duodenal ulcer patients who
were not classified as being cimetidine responder or nonresponder.
Although cimetidine has resulted in a decline in the number of
elective operations for duodenal ulcer (Venables 1981); Bardhan and
Hinchcliffe 1981; Venables 1980; Hunt 1981; Wyllie, Clark, Alexandei—
Williams, Bell, Kennedy, Kirk and McKay 1981; Goggan, Lambert and
Langman 1981), there have been reports of cimetidine either not
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affecting or increasing the number of operations for perforated ulcer
(Price and Elder 1981; McKay and McArdle 1981). Indi cations for surgery
are failed medical treatment with severe, frequent attacks or complicat¬
ions such as haemorrhage, perforation and pyloric stenosis. Contra¬
indications remain as mild or infrequent attacks, other disease or bad
anaesthetic risk. Cimetidine has not altered these indications and,
therefore, failure to respond to blockade is not necessarily an
indication for surgery although patients who continue to meet criteria
of nonresponse should be offered surgery.
One question which needs to be answered is "will vagotomy cure the
cimetidine failures, or is more radical surgery required"? The results
suggest that proximal gastric vagotomy should result in a low relapse
rate compared to cimetidine. Some reports suggest that nonresponders
do badly with vagotomy while others recommend this form of surgery
(Venables 1980; Valleur, Adam, Alasseur, Bitoun, Hautefeuille 1979;
McWhinnie, Gray, Smith, Gillespie 1980; Bardhan 1981; Blackett and
Johnston 1981). What are the reasons for these differences? Blackett
and Johnston 1981) report a 16% recurrence rate after highly selective
vagotomy both before and after the introduction of cimetidine. Venables
(I98O) thought that 16.6% recurrence rate after highly selective vago¬
tomy in nonresponders was cause for concern, particularly when compared
with a 2% two year recurrence rate before cimetidine. A recent review
(Gillespie 1982) found a 15~20% recurrence rate with proximal gastric
vagotomy, and it may well be that high recurrence rates are associated
with proximal gastric vagotomy rather than cimetidine failures. Re¬
currence rates are usually judged endoscopica11y whereas before
cimetidine, such a strict method of assessment was rarely available.
The silent ulcer is now a well recognised entity in endoscopic clinical
trials. Vagotomy results in division of both sensory and secretory
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nerves, which, before endoscopy, might have resulted in a large number
of silent ulcers after surgery, thus giving falsely low relapse rates.
Surgery is perhaps more effective at providing long term relief
of symptoms, but is a high price to pay if attacks have been infrequent.
Cimetidine is probably slightly less expensive than surgery (Pounder
1981; Venables 1981) and has no mortality. Long term side effects with
cimetidine remain unknown and although surgery is well tried, one report
(Stalsberg and Taksdal 1971) has shown a sixfold increase in the risk of
gastric carcinoma in the gastric remnant following gastrectomy which
could be attributed to prolonged achlorhydria.
Although there are disadvantages to both cimetidine and surgery,
if the latter is indicated, this study suggests nonresponders should
do as well as other duodenal ulcer patients, irrespective of their
response to H2 blockade. Nonresponse, therefore, is not an indication
for more radical surgery.
The results so far are contradictory in that although vagotomy
was more effective than cimetidine alone, adding atropine 2.k mg/day,
which should inhibit vagal drive, provided no additional effect. It was
therefore decided to look at vagal function further.
Pepsin secretion is mainly a result of vagal stimulation (Venables,
Wheldon, Johnston 1975; Venables and Johnston 1969; Wilson, Dymock and
Cowley 197^; Berstad, Peterson, Roland and Liavig 1973) and , therefore,
to investigate cholinergic stimuli in more detail, it was decided to






5.1 The effect of cimetidine on nocturnal pepsin secretion. The previous
experiments have all suggested that nonresponse may be due to increased
vagal drive. Pepsin is released after cholinergic stimuli and it was,
therefore, decided to measure the effect of cimetidine on nocturnal
pepsin secretion in a group composed of 12 nonresponders and 6 responder
duodenal ulcer patients.
Pepsin is usually measured at pH2 by acting on haemoglobin or
albumin to release tyrosine which can be read at 280nm or measured by
reaction with folin phenol reagent. Both methods require separation of
the substrate and products before analysis can be completed. The activ¬
ity of pepsin is then compared against hog pepsin preparations which
are variable purity and potency.
Gray and Billings (1982) have described a technique of measuring
peptic activity which offers advantages over previous methods. They
devised a substrate consisting of an a 1 bum i nt>romPhenol blue complex
which is attacked at pH 2.0 to release the dye in a reaction which
follows zero order kinetics. The system was developed into an auto¬
mated kinetic assay which eliminated the necessity of separating
unchanged substrate from the released product.
The analysis is carried out on a COBAS centrifugal analyser which
calculates the best regression line and presents the results in intei
national units. The substrate is made up by taking 3ml of Brcmphenol
Blue 0.Ommo1/1) dissolved in the minimum amount of ethanol, made up
with pH 2.0,0.k molar g1ycine-hydrocholoric acid buffer and adding
1.8ml of bovine albumin (Sigma) lOg/lOOml. The resulting solution is
made up to 20ml with glycine buffer. Gastric juice is added to this
substrate in a reagent boat of a Cobas analyser and enzyme activity
monitored at 605 bm. over a period of five minutes. The period of
zero-order kinetics is used to determine the absorbance change per
minute from which peptic activity is calculated in international
un i ts per 1it re.
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Gastric juice was taken from six normal subjects after intramuscular
pentagastrin 6yg/kg and used to compare the method of Gray and Billings
wi th that of Berstad 0 97Q].
Some of the advantages of this pepsin assay are: standardisation
of the method , expression of the peptic activity in international units
9
easily made and stable reagent, substrate and products do not require
separation, and finally the whole analysis is carried out on an automatic
analyser with Its attendant advantage of high throughput and minimal
operator involvement.
Twleve nonresponders mean age 34 years (range 20-53) and six res-
ponders, mean age 31.3 years Crange 22-48) were studied over two 24 hour
periods receiving either no treatment or cimetidine in standard dose.
The protocol was identical to that described in 2.3.1, but in addition
to taking a sample of gastric juice to calculate acid output, a 5ml
sample was immediately frozen at -20°C and stored the following day at
~90°C for later estimation of peptic activity.
When the results of peptic activity became available, concentration
was multiplied by volume to obtain a value of pepsin output.
5.2 The effect of ranitidine on nocturnal acid and pepsin output. Six
nonresponders, mean age 32.5 years (range 20-36) were studied over three
24 hour periods receiving either no treatment, cimetidine 400mg b.d.
or ranitidine 150mg bd. The dose of cimetidine was different from the
previous experiments because of the change in recommended dose (Burland,
Brunet, Hunt, Melvin, Mills, Vincent, Milton-Thompson 1980; Kerr 1981;
Eckardt I98I). The study was also designed to compare the new cimetidine
dose with the twice daily ranitidine regime at decreasing 24 hour intra¬
gastric acidity. For this reason, the nasogastric tube was passed at
0730 and data collected for the whole 24 hour period.
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Overnight, volume of secretion was. recorded and 5ml samples taken
hourly for pH estimation followed by titration to pH 7, and for immediate
freezing at -20°C followed by storage at -9'0°C for later pepsin estimation.
5.3 The effect of impromidine on pepsin secretion in normal subject.
Ten healthy volunteers (mean age 26 years, mean weight 73kg) fasted from
midnight and attended the ward at 0730. A size lA French Salem sump naso¬
gastric tube (Shearman Laboratories) was passed and position checked by
water aspiration. The stomach was emptied by hand suction, the subject
placed supine and the nasogastric tube connected to a pump for contin¬
uous mechanical aspiration at -50mm mercury.
Samples of gastric juice were taken every 10 minutes throughout the
study, volume and pH recorded and a 5ml sample titrated to pH 7.0 with
0.1 sodium hydroxide to calculate acid output. A second 5ml sample was
immediately frozen at -20°C and stored at -90°C for later pepsin estim¬
ation.
Continuous suction was interrupted every 5 minutes by manual syringe
aspiration to ensure more accurate collection (Baron 19781. Samples,
were taken over a 90 minute basal period and basal acid and pepsin out¬
puts calculated by the sum of the last six 10 minute collections. A
19 gauge butterfly cannula was then inserted into a forearm vein and an
intravenous infusion of impromidine lOyg/kg started. Samples were coll¬
ected for a further 90 minutes, after which, the subjects were given
food. Peak acid and pepsin outputs were calculated from the sum of the
last six 10 minute collections.
5. A The effect of cimetidine on overnight serum glucose and insulin.
The serum samples obtained from six patients in study 2.3.2 were trans¬
ported in cardice to Dr.David Saunders at the Department of Physiology,
Newcastle Medical School who kindly agreed to measure serum glucose
67.
and serum insulin on the no treatment and cLmetidine regimens.
5.5 The effect of cimetidine lg/day combined with atropine 4.8mg/day.
Seven nonresponders mean age 31.3 years (range 20-39), mean weight 75.^
kg (range 67.3~8l.8) were studied over four separate 2k hour periods
receiving either no treatment, cimetidine 400mg bd., atropine ^.Smg/day
or a combination of the cimetidine and atropine. Both drugs were taken
with food, the atropine being given in four divided doses. Otherwise




6.1 The effect of cimetidine on nocturnal pepsin output. The correlation
of the method of Gray and Billings with that of Berstad using juice ob¬
tained from six pentagastrin tests in normal subjects is shown in Figure
6.1.1 (r=0.984).
Mean nocturnal (0100-0700) acid and pepsin output for all the duo¬
denal ulcer patients receiving the two treatments are shown in Figure
6.1.2. Nocturnal pepsin output increased from 1.55 + 2.74 lU/hr on no
treatment to 3.88 +_ 5.17 lU/hr on cimetidine while acid output decreased
from 5.64 +4.49mmol/hr on no treatment to 3.71 + 3.27 mmol/hr on cimeti¬
dine. The increase in pepsin output was significant at the 5% level and
the decrease in acid output significant at the level.
Table 6.1 shows the effect of cimetidine in the two groups of
responders and nonresponders. It can be seen that the highest mean
pepsin output was in the nonresponder group when receiving cimetidine.
The standard deviations were large, the number of patients small and,
therefore, the result was not significant.
The responder patients decreased their acid output from 5-10
mmol/hr to 1.20 mmol/hr, but the nonresponders decreased acid output
from 5.93mmol/hr to 3.83mmol/hr with cimetidine.
The relationship between acid and pepsin output showed no cor¬
relation on no treatment (r=0.04 NS), but on cimetidine the correlatfon
became highly significant (r=0.64, p< 0.0001). The mean hourly values
of acid and pepsin output in four patients chosen at random are shown
in Figure 6.1.3. The increased correlation with cimetidine can be
clearly seen.
6.2 The effect of rantidine. All patients tolerated this study well.
Mean 24 hour hydrogen ion activity decreased from 34.49 + 22.87 mmol/1
on placebo to 23.67 + 20.12 with cimetidine (p< 0.Q5) and to 12.85 +_
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and p< 0.05 compared with cimetidin^.
Mean nocturnal hydrogen ion activity (Figure 6.2.1) decreased from
44.46 + 15.97 mmol/1 on placebo to 24.78 +_ 19.06mmol/l with ci.metidine
(NS) and to 23.2 + 19.74 with ranitidine (p< 0.01 compared with placebo
and NS compared with cimetidine).
Nocturnal volume of gastric secretion (Figure 6.2.2) decreased from
57.64 -t 37.79ml/hr on placebo to 54.97 + 29.85ml/hr on cimetidine (NS.L
and to 34.53 19.27 on ranitidine (NS compared with placebo and NS
compared with cimetidine).
Mean nocturnal acid output (Figure 6.2.3) decreased from 5.19 +
4.13mmol/hr on placebo to 3.79 + 2.98mmol.hr on cimetidine (NS) and to
1.67 + 1.82mm91/hr on ranitidine (p< 0.05 compared with placeho and
p< 0.05 compared with cimetidine).
Mean nocturnal pepsin output is shown in Figure 6.2.4 . On no
treatment, pepsin output was 1.6 + 1.88 lU/hr compared to 2.9 + 3.2
lU/hr on cimetidine and 3.12 +2.14 lU/hr on ranitidine.
Although the numbers are small, these results suggest ranitidine
is not significantly better than cimetidine at decreasing nocturnal
H+ activity or volume of secretion and that ranitidine also stimulates
pepsin output.
6.3. I.mpromid ine in normal subjects. All subjects tolerated the study
well. Acid and pepsin output are shown in Figure 6.3.1. Mean basal
acid output was 4.11 + 3.88mmol/hr which rose to 29.72 +_ 8.2 mmol/hr
with impromidine (p< 0.001). Mean basal pepsin output was 3.65 3.63
lU/hr which decreased to 0.21 + 0.18 lU/hr with impromidine (p< 0.02).
The decrease in pepsin output was noted in every subject. Even in the
first 30 minutes of impromidine infusion, mean pepsin output decreased
to 0.8lU/hr which suggests that this decrease is a true decrease in
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and pepsin outputs in response to impromidine.
These results suggest that ^ agoni&m Increases acid output but
decreases pepsin output in normal subjects.
6.4. G1ucose and Insulin. Sufficient serum had been stored from study
2.3.2 to measure glucose levels on the two treatments in six patients and
insulin levels on the two treatments in four patients.
The results are shown in Figures 6.4.1 and 6.4.2. It can be seen that
there was no difference between hourly glucose or Insulin levels on no
treatment and cimetidine.
6.5. Cimetidine combined with atropine 4.8mg/day. Mean nocturnal hydro¬
gen ion activity (Figure 6.5.1) decreased by 39% with cimetidine lg/day
(NS) , by 19% with atropine 4.8mg/day (NS) and by 69% with the combination
of cimetidine lg/day and atropine 4.8mg/day (p<0.05 compared with placebo
NS compared to cimetidine lg/day and p< 0.001 compared with atropine
alone). This result was not statistically different from cimetidine
lg/day because one patient had a remarkably good response to cimetidine
alone which was slightly better than the combination.
Mean 24 hour hydrogen ion activity (Figure 6.5.2) decreased by 35%
with cimetidine (NS) by 28% with atropine (NS) and by 73% with the com¬
bination (p< 0.01 compared with no treatment, p< 0.001 compared with
cimetidine and p < 0.001 compared with atropine).
Volume of gastric secretion is shown in Figure 6.5.3. it can be
seen that volume again did not decrease significantly in the nonrespon-
ders on cimetidine, but there was a highly significant reduction from
80.5ml/hr on placebo to l6.5ml/hr with the combination (p<0.0l). It
can also be seen that atropine alone decreased volume when compared to
placebo (p< 0.02) but this decrease was not as great as the combination.
Acid output (Figure 6.5.4) decreased by 83% with the combination
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and NS compared with atropine alone).
Mean nocturnal pepsin output (Figure 6.5.5) was 3.03 3.91 I.U/hr
on no treatment, *4.0 +_ 3.2 lU/hr on cimetidine alone and 1.1+ 1.13 lU/hr
on the combination (p< 0.01 compared with cimetidine alone}.
The result shows that combination of atropine 4.8mg/day with cime¬
tidine lg/day is superior to either drug alone at decreasing 2b hour
intragastric acidity, nocturnal intragastric acidity, nocturnal volume
of secretion, acid output and nocturnal pepsin output.
CHAPTER 7
DISCUSSION
7.1 Nocturnal Pepsin Secretion. The method of measuring pepsin concen¬
tration used in this thesis had an extremely good correlation with another
more standard method (Berstad 1970) but had the advantage of being quicker
and providing a large throughput. Taylor (1970) has shown that peps.in
may be separated into several proteolyte enzymes. However, although
some of these enzymes are closely associated with duodenal ulcer, it is
probably total proteolytic activity which keeps an ulcer active because
total peptic activity is related to ulcer activity (Taylor 1970; Elder
1975; Venables 1979; Achord 1978; Helmer.1937; Achord 1981).
The study confirms the results of the previous experiments by
showing less decrease in acid output in the nonresponders compared with
other duodenal ulcer patients. The findings also suggest that nocturnal
intragastric pepsin is increased by cimetidine in duodenal ulcer patients.
The highest nocturnal pepsin levels were found in the nonresponders
receiving cimetidine.
Animal work suggests that duodenal ulcer does, not occur in the
absence of pepsin (Schiffrin and Warren 19^2) and in man, peps.in secretion
has been correlated with disease activity (Vanzant, Osterberg, Alverez,
Rivers 1933; Taylor 1970; Elder 1975; Venables 1979; Achord 1978;
Helmer 1937). Increased pepsin secretion is unlikely to be of clinical
benefit and may be an important cause of nonresponse.
Cimetidine has been shown to increase ulcer healing rates (Bodemar
and Walan 1976; Gray, McKenzie, Smith, Crean, Gillespie 1977; Domschke,
Domschke, Lux, Demling 1976) and previous reports suggest that cimeti.dine
either has no effect or decreases nocturnal pepsin secretion (Longstreth,
Malagdelada, Go 1975; Longstreth, Go, Malagdelada 19.76; Saunders,
Cargill, Wormsley 1977). These reports contradict the findings of this
study.
Pepsin is irreversibly denatured above pH 6.0 (Figure 7.1.1)










(Goulding, Borsook, Wasteneys 1927; Piper and Fenton 1973; Berstad
I982). If any treatment results in a rise in pH, pepsin deactivation
will result }providing a falsely low pepsin measurement. In nonrespon-
ders, it has already been demonstrated that cimetidine has a decreased
effect on hydrogen ion activity and, therefore, pepsin is unlikely to
be denatured. Previous reports measuring the effect of cimetidine on
pepsin secretion were all performed in either normal subjects or
duodenal ulcer patients who had a much greater decrease of hydrogen ion
activity than any of the present studies.
The increase of pepsin output observed in this study occurred in
both nonresponders and other duodenal ulcer patients. The question
which arises is "does this increase occur as part of the pathophysiology
of duodenal ulcer, or part of a physiological pathway in normal
subjects"?
Duodenal ulcer is thought to be associated with increased vagal
drive (Dragstedt 19^5) and there have been several unexplained reports
suggesting a combination of vagal stimulation with an ^"receptor
antagonist results in a greater intragastric pepsin concentration than
produced by vagal stimulation alone (Carter, Forrest, Logan, Ansel 1,
Lidgard, Heading and Shearman 1976; Sheers and Roberts 1981; Gibson,
Hirschowitz and Hutchison 197*0. Thus H^ blockade might only increase
pepsin output in the presence of increased vagal tone.
Several other workers have noted increased pepsin output with
cimetidine. Browning and Heathcote 0982) found an increase in pepsin
concentration in the cat after cimetidine; Stage, Stadil and
Ffscherman (1978) demonstrated a significant increase in basal pepsin
output in nine patients with Zol1inger-El1ison syndrome receiving
cimetidine and Pikkarainen (1981) found an elevated serum pepsinogen
after cimetidine treatment in duodenal ulcer patients.
Before Investigating normal subjects, it was decided to see if
other antagonists resulted in increased pepsin secretion or whether
this is an effect peculiar to cimetidine. The next study, therefore,
measured nocturnal pepsin secretion in duodenal ulcer patients
receiving ranitidine.
7.2 Ranitidine. Ranitidine is a new furan histamine H^-receptor
antagonist which inhibits all forms of stimulated acid secretion
(Mullei—Lissner, Sonnenberg, Eichenberger, Blum 1981; Sheers and
Roberts 1981) and has been shown to provide a 70? inhibition of mean
2k hour intragastric acidity and a 30% reduction of nocturnal acid out¬
put (Walt, Male, Hunt, Rawlings, Milton-Thompson and Misiewicz 1981).
The aim of this study was to compare the effect of this new, more
potent H2~receptor antagonist with cimetidine at decreasing 2k hour
intragastric acidity, volume of nocturnal secretion and acid output
in nonresponders and to investigate the effect of ranitidine on
nocturnal pepsin secretion.
The study demonstrated that ranitidine was more effective at
reducing 2k hour intragastric acidity, nocturnal intragastric acidity,
and nocturnal acid output than cimetidine. Like cimetidine in the
previous studies, ranitidine had no significant effect on volume of
gastric secretion. This may have been because the number of patients
was small. However, acid output and intragastric acidity did not
decrease significantly. Work with ranitidine in dogs (Brittain and
Daly 1981) has shown that only after a very large reduction in volume
(78-80?) is concentration of acid reduced - and then by only about
20?. Thus, whatever mechanism is involved in nonresponse to cimetidine,
it is likely that the same mechanism exists for ranitidine. This is
also supported by the present observed reduction of 63? in
intragastric acidity and 70? in nocturnal acid output compared to
70% and 90% respectively reported by Walt, Male, Hunt, Rawlings, Milton-
Thompson and Misiewicz (1981).in unselected duodenal ulcer patients.
There have been three previous reports of ranitidine healing
cimetidine resistant ulcers (Mohammed, Mitchell, McKay 1981; Brunner
1981; Schultz 1982), but these were not controlled studies and it is
known that continued treatment with cimetidine results in increased
healing rates (Bardhan I98O). A recent report suggested that although
ranitidine heals cimetidine resistant ulcers, cimetidine can also heal
ranitidine resistant ulcers (Mazzacca, D'Agostini, D'Arienzo, Piai,
Sabbat ini and Verre 1 982) „
Clinical trials comparing rantidine with cimetidine have tended
to show slightly higher healing rates with ranitidine but none of these
have been significant (Langman, Henry, Ogilvie 1981; Walt, Trotman,
Frost, et al 1981; Costello, Fielding and Lee 1982)0 However, to demon¬
strate less than a 10% difference in healing rates between two different
treatments requires extremely large numbers of patients.
The present study suggests that ranitidine increases nocturnal
pepsin output to a greater extent than cimetidine. The number of patients
was; small and the standard deviations quite large and, therefore, the
difference was not significant. However, it is in direct contrast to
the acid results and, therefore, must be suggestive.
Mu'l 1 er-L i ssner, Sonnenberg, Eichenberger and Blum (1 981) have
shown that sham feeding stimulated pepsin output decreased with raniti¬
dine, but they also showed over a hundredfold decrease in acid concen¬
tration which would have resulted in pepsin deactivation. Sheers
and Roberts (1981) found pepsin concentration increased when ranitidine
was added to a vagal stimulus; Cavallini, Angelini, Fratton, Ruta,
Rosa, Delorio and Scuro (1982) found an increased pepsin in gastric
juice after ranitidine treatment and Mario, Plebani, VionellO, Forini,
Giordano, Scalabrin, Cerotti and Naccerato (1980) found increased s.erum
pepsinogen after ranitidine treatment in duodenal ulcer patients.
It thus, appears that blockade results in increased intragas¬
tric pepsin secretion in duodenal subjects. Normal subjects do not show
this effect because either it is part of the pathophysiology of this
disease or the associated greater increase in pH with blockade in
healthy individuals results in pepsin deactivation. .
If blockade results in a rise of intragastric pepsin then
agonism should produce a fall. As agonism is accompanied by an
increased acid secretion, autodestruction of pepsin will not be a prob¬
lem, even in normal subjects. Impromidine, a recently described
selective agonist (Hunt, Mills, Beresford, Billings, Borland and
Milton-Thompson 1980) was, therefore, used to measure basal and stimu¬
lated pepsin output in a group of healthy volunteers.
7.3 Lmpromidine in normal subjects. The aim of this study was to
measure the effect of impromidine on pepsin secretion in normal subjects.
The result shows a significant decrease in pepsin output after
impromidine and a significant increase in acid secretion. This suggests
there is a physiological pathway in man by which histamine inhibits
pepsin secretion. The findings do not support a pathophysiological
mechanism of pepsin secretion associated with duodenal ulcer alone.
There have been no previous reports of pepsin secretion with
impromidine but several authors have described pepsin output in res¬
ponse to histamine. Babkin (1930) found pepsin output decreased with
histamine, but he thought this might be a "washout" phenomenon. The
present study does not support this concept because pepsin output de¬
creased even in the first half hour of impromidine infusion.
Alley was the first to suggest that histamine had an inhibitory
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effect on the peptic cell. In 1935, he wrote "histamine, while stimu¬
lating the parietal cells, inhibits that action of the vagi on the
peptic cells preventing the discharge by them of zymogen granules".
Hirschowitz has also suggested that histamine inhibited pepsin output
(Hirschowitz 1957) in the dog and later demonstrated a dose response
effect (Hirschowitz, Sachs and Hutchison 1974). Emas and Grossman (19571
have shown that in the dog, histamine in large doses inhibits pepsin
secretion and more recently Gibson, Hirschowitz and Hutchison (J 9.74)
suggested that histamine may have an inhibitory role on the peptic cell
in man.
Pepsin is released by chief cells which may be stimulated either
locally, hormonally, or neuronally. Johnson(l972a; 1972b) has shown
that local application of acid results in increased pepsin release.
However, although Hirschowitz and Gibson (1973) and Guldvag and Berstad
(1982a) have postulated a direct inhibitory action of histamine on the
chief cell, studies on isolated canine and rabbit cells (Sol, Amirian,
Thomas, Ayalon 1982; Kapadia, Donaldson 1978; Kasbekar, Jensen and
Gardner 1982) have shown neither stimulation nor inhibition of pepsin
output in response to histamine.
Secretin is known to stimulate pepsin release (Sol, Amirian,
Thomas, Aylon 1982; Raufman, Kasbekar, Jensen and Gardner 1982; Berstad,
and Peterson 1970; Berstad, Peterson, Roland and Liavig 1973; Brooks,
Isenberg and Grossman 1979) but this hormone does not increase with
ranitidine after tetragastrin (Yabana, Kawai et al 1982) or with
ranitidine after either a fast or a meal (Tomassetti, Pazzaglia,
Stanghel 1 ini, Bonora, Favaro, Vezzadini and Labo 1 982) .
Cimetidine is known to increase serum gastrin (Spence, McCormick,
Oliver and Celestin 1978; Forrest, Fettes, McLoughlin and Heading 1978;
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Richardson 1978) and might be involved in controlling pepsin secretion.
Schofi.eld (J 958) demonst rated that food decreased pepsin output in the
dog Heidenhein pouch which led him to conclude inhibition may occur via
a hormonal pathway. In the antrectomised dog model, Olbe, Ridley and
Uvnas (1968) demonstrated both gastrin and histamine decreased vagally
stimulated pepsin secretion and more recently Magee and Hu (1975) have
suggested gastrin may have an inhibitory effect on pepsin release. The
same group (Kondo and Magee 1977) later demonstrated that the antrum
is the source of an agent which inhibits pepsin secretion but they favou¬
red a mechanism involving sympathetic nerves rather than gastrin. Thus,
although cimetidine increases gastrin release, it does not explain an
associated increase in pepsin as gastrin, if anything, decreases pepsin
secretion. However, cimetidine is known to have a number of other hor¬
monal effects (Edwards 1981), any of which might be responsible for
raising intragastric pepsin.
Pepsin is also released as a result of cholinergic stimulation
(Venables, Wheldon and Johnston 1975; Venables and Johnston 1969; Wilson,
Dymock and Cowley 197^; Berstad, Peterson, Roland Liavig 1973) and if
histamine has an inhibitory role on the vagus nerve then cimetidine
should decrease vagal inhibition resulting in increased pepsin output.
Maybury and Cari—Locke have shown that cimetidine had no effect on
insulin stimulated secretion in cimetidine nonresponders which supports
blockade increasing vagal drive. The lack of effect on volume of
secretion shown throughout this thesis, the increased pepsin secretion
with cimetidine and ranitidine and the close correlation of acid and
pepsin output with cimetidine also support this theory. The latter
observation demonstrated in study 6Jsuggests that when on cimetidine,
acid and pepsin are under the same control which might well be vagal
in origin.
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Vagotomy results in decreased histamine stimulated acid secretion
(Payne and Kay 1962; Rosato, Rosato, and McFadyen 1971) and does not
support histamine having an inhibit-ory action on the vagus unless there
are two types of nerve fibre, one affecting chief cells and one affect¬
ing parietal cells. Ingolby, Man and Spencer (1982) have shown that
although sham feeding results in increased intragastric histamine,
insulin stimulated secretion does not, suggesting the presence of two
types of vagal fibre.
Insulin induced hypog1ycaemia increases vagal drive with resulting
increased pepsin output. If cimetidine stimulated Insulin release,
this could well explain the previous results. It was, therefore,
decided to measure nocturnal serum insulin and glucose in response to
cimetidine.
7.5 Glucose and Insulin. The result demonstrated that cimetidine had
no significant effect on serum insulin or serum glucose in cimetidine
nonresponders and, therefore, does not support the suggestion that
increased vagal drive results from nocturnal hypog1ycaemia.
Two possibilities remain; either cimetidine causes release of a
hormone resulting in increased pepsin output or cimetidine increases
vagal drive in some types of vagal fibre which are normally inhibited
by histamine. The latter possibility could be explained by a decreased
synthesis or release of enkephalins which are known to inhibit acid
and pepsin secretion (Sullivan, Corke and Darwish 1982; Konturek, Kwiecien,
Obtulowicz, Swierczek, Oleskyend and Coy 1982) and are found in large
quantities in the gastric antrum (Ed i n, Lundberg, Terenius 1980;
Polak, Sullivan, Bloom, Facer and Pearce 1977) and vagus nerve
(Alumets, Hakanson, Sundler and Chang 1978). However, both cimetidine
and enkephalin analogues result in increased serum prolactin secretion
(Knigge, Wollesen, Dejgarrd, Thuesen, and Christiansen 1981;
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vonGraffenried, delPozo, Roubieck, Krebs, Poldinger, Burmeister and
Kerp 1978; Stubbs, Delitala, Jones, Jeffcoate, Edwards, Ralter, Besser,
Bloom and Alberti 1978) and, therefore cfmetidine would, if anything be
expected to increase enkephalin release.
The aim of this thesis set out to ask why patients do not respond
to H2 blockade and how these nonresponders should be treated. It did
not include investigating the mechanism involved in nonresponse and,
therefore, other studies, perhaps measuring overnight hormone or
enkephalin release were not performed. One final question, however,
is to ask how the nonresponder should be treated. The previous discus¬
sion has.suggested that increased vagal drive may result with cimetidine
treatment. To inhibit this response, the logical approach would be
to add an anticholinergic agent to cimetidine yet the result of
study 3.3 and that reported by Pounder, Hunt, Vincent, Milton-Thompson
and Misiewicz (1977) showed no benefit from combination therapy. Pre¬
vious reports, however, (Thjod 1 eifsson and Wormsley 197^*, Londong,
Londong, Weber and VonWerder 1980) did find benefit from the addition
of an anticholinergic agent. The study in 3.3 and that previously
reported by Pounder and colleagues were performed at the Royal Naval
Hospital, Haslar, using fit naval ratings whose mean weight in the
present study, for example, was 73-3 kg. Few of these subjects
complained of side effects from the atropine and, therefore, the dose
on a body weight basis may have been insufficient. It was, therefore,
decided to repeat the study combining cimetidine with atropine but
to increase the dose to the maximum considered safe by the British
Pharmacopea of 4.8mg/day.
7.5 Cimetidine combined with atropine ^.Smg/day. The aim of this
study was to measure the effect of cimetidine lg/day combined with
atropine 4.8mg/day on 2k hour intragastric acidity, nocturnal volume
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of gastric secretion, nocturnal acid output and pepsin output in non-
responders. The result is in agreement with previous experiments, sugges¬
ting cimetidine alone has no significant effect on the volume of nocturnal
gastric secretion. The addition of atropine at the increased dose pro¬
duced a dramatic decrease in 2b hour hydrogen ion activity, nocturnal
hydrogen ion acitivity, nocturnal volume of secretion and nocturnal
acid output. Cimetidine alone produced an increase in nocturnal pepsin
output which was abolished by the addition of atropine.
These results suggest that insufficient dose of atropine was the
probably explanation for the lack of benefit of atropine 2.4mg/day in 3.3
and in the study reported by Pounder, Hunt, Vincent, Milton-Thompson
and Misiewicz (1977). The present study also suggests that whatever
mechanisms involved in failure to respond to cimetidine, it is abolished
by adding an anticholinergic agent.
The decrease in peptic activity with the addition of atropine
supports the theory of increased vagal drive by cimetidine. The
result could, however, also be explained by the combination producing
a greater increase in pH than with cimetidine alone and, therefore,
increased pepsin deactivation.
Whatever mechanism is involved, adding an anticholinergic agent
should result in increased healing rates. Atropine however has notable
side effects in the present study, and all patients complained that
these were unacceptable.
Pirenzepine is a new antimuscarinic agent with a high affinity
for receptors at the parietal cell and, therefore, is without systemic
side effects (Jaup 1981).
Gabryelewicz, Serosick, Laszewicz and Piotrowski (1982) have
shown ranitidine combined with pirenzepine inhibits pentagastrin stimu¬
lated acid secretion better than ranitidine alone and Londong, Londong,
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Weber and VonWerder (1980) have shown that pirenzepine combined with
cimetidine Inhibits pentagastr in stimulated acid secretion better than
either drug alone. Mignon, Vallot, Galmiche, Dupas and Bonfils (.19.80)
have used this latter combination with some success in the Zollinger-
Ellison syndrome. Nocturnal acid output has been inhibited better with
a combination of an H^-receptor antagonist with pirenzepine than an H^-
antagonist alone, and has been recommended as a form of therapy for the
resistant ulcer (Scholton, Schuchert, Fritsch, Muller and Hengels 19.82).
Roberto, Nicola and Sergio (1982) gave a combination of cimetidine and
pirenzepine to 15 patients who failed to respond with cimetidine or
pfrenzepine both given separately for one month. Thirteen of the 15
patients healed their ulcer within one month of taking the combination
therapy. Although this was not a controlled study, it supports the
work in this thesis that cimetidine nonresponders should be treated




8. Conclus ion. It has been demonstrated that in nonresponders,
cimetidine has no significant effect on volume of gastric secretion
and a decreased effect on intragastric pH and nocturnal acid output when
compared with a unselected group of duodenal ulcer patients. The drug
may also cause increased release of pepsin in these patients:. It is
suggested that the combination of these factors results in failure to
heal or early relapse. The mechanism of increased pepsin output with
cimetidi'ne was thought to be an effect because ranitidine resulted
in increased intragastric pepsin, and the agonist impromidine in¬
hibited pepsin release.
increasing the dose of cimetidine does not improve control of acid
secretion despite adequate drug absorption. Combination of cimetidine
with an anticholinergic agent however, results in a dramatic decrease
of both acidity and pepsin secretion.
It is, therefore, probable that addition of an anticholinergic
agent to cimetidine will result in healing of a cimetidine resistant
ulcer. If, however, surgery is indicated, good results are to be expected
from proximal gastric vagotomy as this gives better control of acidity
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